IDH1 and central nervous system cancer: CDKN2A mutations represent a negative prognostic factor in terms of survival in both diffuse IDH-mutant and IDH-wildtype gliomas, with lower impacts on grade 2 and 3 gliomas than grade 4 gliomas [26,41,42,43].